---
document_datetime: 2025-12-29 07:37:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/crixivan.html
document_name: crixivan.html
version: success
processing_time: 0.1052708
conversion_datetime: 2025-12-30 11:05:54.070387
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Crixivan

[RSS](/en/individual-human-medicine.xml/66326)

##### Withdrawn

This medicine's authorisation has been withdrawn

indinavir Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Crixivan](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 26 March 2021, the European Commission withdrew the marketing authorisation for Crixivan (indinavir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp &amp; Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Crixivan was granted marketing authorisation in the EU on 04 October 1996 for treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults in combination with antiretroviral nucleoside analogues. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2001 and 2006. It was then granted unlimited validity in 2011. The product had not been marketed in the EU since 2020.

The European Public Assessment Report (EPAR) for Crixivan is updated to indicate that the marketing authorisation is no longer valid.

Crixivan : EPAR - Summary for the public

Reference Number: EMA/721612/2016

English (EN) (631.95 KB - PDF)

**First published:** 12/11/2008

**Last updated:** 07/07/2022

[View](/en/documents/overview/crixivan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-42)

български (BG) (724.42 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/bg/documents/overview/crixivan-epar-summary-public_bg.pdf)

español (ES) (631.54 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/es/documents/overview/crixivan-epar-summary-public_es.pdf)

čeština (CS) (703.68 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/cs/documents/overview/crixivan-epar-summary-public_cs.pdf)

dansk (DA) (630.85 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/da/documents/overview/crixivan-epar-summary-public_da.pdf)

Deutsch (DE) (632.72 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/de/documents/overview/crixivan-epar-summary-public_de.pdf)

eesti keel (ET) (628.26 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/et/documents/overview/crixivan-epar-summary-public_et.pdf)

ελληνικά (EL) (726.63 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/el/documents/overview/crixivan-epar-summary-public_el.pdf)

français (FR) (632.1 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/fr/documents/overview/crixivan-epar-summary-public_fr.pdf)

hrvatski (HR) (659.37 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/hr/documents/overview/crixivan-epar-summary-public_hr.pdf)

italiano (IT) (630.9 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/it/documents/overview/crixivan-epar-summary-public_it.pdf)

latviešu valoda (LV) (685.03 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/lv/documents/overview/crixivan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (653.46 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/lt/documents/overview/crixivan-epar-summary-public_lt.pdf)

magyar (HU) (697.74 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/hu/documents/overview/crixivan-epar-summary-public_hu.pdf)

Malti (MT) (686.24 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/mt/documents/overview/crixivan-epar-summary-public_mt.pdf)

Nederlands (NL) (631.42 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/nl/documents/overview/crixivan-epar-summary-public_nl.pdf)

polski (PL) (703.25 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/pl/documents/overview/crixivan-epar-summary-public_pl.pdf)

português (PT) (631.52 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/pt/documents/overview/crixivan-epar-summary-public_pt.pdf)

română (RO) (652.43 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/ro/documents/overview/crixivan-epar-summary-public_ro.pdf)

slovenčina (SK) (702.94 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/sk/documents/overview/crixivan-epar-summary-public_sk.pdf)

slovenščina (SL) (695.58 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/sl/documents/overview/crixivan-epar-summary-public_sl.pdf)

Suomi (FI) (628.51 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/fi/documents/overview/crixivan-epar-summary-public_fi.pdf)

svenska (SV) (631.31 KB - PDF)

**First published:**

12/11/2008

**Last updated:**

07/07/2022

[View](/sv/documents/overview/crixivan-epar-summary-public_sv.pdf)

## Product information

Crixivan : EPAR - Product Information

English (EN) (1.96 MB - PDF)

**First published:** 23/07/2009

**Last updated:** 07/07/2022

[View](/en/documents/product-information/crixivan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-953)

български (BG) (4.27 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/bg/documents/product-information/crixivan-epar-product-information_bg.pdf)

español (ES) (2.07 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/es/documents/product-information/crixivan-epar-product-information_es.pdf)

čeština (CS) (3.28 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/cs/documents/product-information/crixivan-epar-product-information_cs.pdf)

dansk (DA) (2.22 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/da/documents/product-information/crixivan-epar-product-information_da.pdf)

Deutsch (DE) (2.16 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/de/documents/product-information/crixivan-epar-product-information_de.pdf)

eesti keel (ET) (1.97 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/et/documents/product-information/crixivan-epar-product-information_et.pdf)

ελληνικά (EL) (4.32 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/el/documents/product-information/crixivan-epar-product-information_el.pdf)

français (FR) (2.13 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/fr/documents/product-information/crixivan-epar-product-information_fr.pdf)

hrvatski (HR) (2.02 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/hr/documents/product-information/crixivan-epar-product-information_hr.pdf)

íslenska (IS) (1.96 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/is/documents/product-information/crixivan-epar-product-information_is.pdf)

italiano (IT) (2.13 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/it/documents/product-information/crixivan-epar-product-information_it.pdf)

latviešu valoda (LV) (3.37 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/lv/documents/product-information/crixivan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.99 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/lt/documents/product-information/crixivan-epar-product-information_lt.pdf)

magyar (HU) (3.5 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/hu/documents/product-information/crixivan-epar-product-information_hu.pdf)

Malti (MT) (4.77 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/mt/documents/product-information/crixivan-epar-product-information_mt.pdf)

Nederlands (NL) (2.05 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/nl/documents/product-information/crixivan-epar-product-information_nl.pdf)

norsk (NO) (1.95 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/no/documents/product-information/crixivan-epar-product-information_no.pdf)

polski (PL) (3.59 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/pl/documents/product-information/crixivan-epar-product-information_pl.pdf)

português (PT) (2.08 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/pt/documents/product-information/crixivan-epar-product-information_pt.pdf)

română (RO) (2.1 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/ro/documents/product-information/crixivan-epar-product-information_ro.pdf)

slovenčina (SK) (3.39 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/sk/documents/product-information/crixivan-epar-product-information_sk.pdf)

slovenščina (SL) (3.26 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/sl/documents/product-information/crixivan-epar-product-information_sl.pdf)

Suomi (FI) (2.09 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/fi/documents/product-information/crixivan-epar-product-information_fi.pdf)

svenska (SV) (2.01 MB - PDF)

**First published:**

23/07/2009

**Last updated:**

07/07/2022

[View](/sv/documents/product-information/crixivan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0104 03/08/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Crixivan : EPAR - All Authorised presentations

English (EN) (630.86 KB - PDF)

**First published:** 27/02/2009

**Last updated:** 07/07/2022

[View](/en/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-154)

български (BG) (653.8 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/bg/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_bg.pdf)

español (ES) (627.79 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/es/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (644.39 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/cs/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (628.33 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/da/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (652.71 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/de/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (627.6 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/et/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (653.17 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/el/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_el.pdf)

français (FR) (649.41 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/fr/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (622.71 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/hr/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (626.91 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/is/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (627.76 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/it/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (645.4 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/lv/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (629.06 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/lt/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (644.77 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/hu/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (669.33 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/mt/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (650.34 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/nl/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (622.6 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/no/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_no.pdf)

polski (PL) (644.99 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/pl/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_pl.pdf)

português (PT) (628.19 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/pt/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_pt.pdf)

română (RO) (628.43 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/ro/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (645.24 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/sk/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (644.11 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/sl/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (621.11 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/fi/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (630.62 KB - PDF)

**First published:**

27/02/2009

**Last updated:**

07/07/2022

[View](/sv/documents/all-authorised-presentations/crixivan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Crixivan Active substance indinavir sulfate ethanolate International non-proprietary name (INN) or common name indinavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE02

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.

## Authorisation details

EMA product number EMEA/H/C/000128 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Marketing authorisation issued 04/10/1996 Revision 39

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Crixivan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (786.28 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 07/07/2022

[View](/en/documents/procedural-steps-after/crixivan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Crixivan : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (708.03 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 07/07/2022

[View](/en/documents/steps-after-cutoff/crixivan-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Crixivan : EPAR - Scientific Discussion

English (EN) (794.66 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 07/07/2022

[View](/en/documents/scientific-discussion/crixivan-epar-scientific-discussion_en.pdf)

Crixivan : EPAR - Procedural steps taken before authorisation

English (EN) (654.89 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 07/07/2022

[View](/en/documents/procedural-steps/crixivan-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Crixivan

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

**This page was last updated on** 12/07/2022

## Share this page

[Back to top](#main-content)